Is Jean Coutu Group PJC Inc. a Buy on Strong Earnings Results?

Pharmacy franchise chain Jean Coutu PJC Inc. (TSX:PJC.A) just reported higher than expected earnings. Time to buy?

| More on:
The Motley Fool

Canadian pharmacy franchise chain Jean Coutu PJC Inc. (TSX:PJC.A) beat analyst earnings estimates on Wednesday, reporting earnings of $0.27 per share, which was $0.02 higher than the consensus analyst estimate of $0.25 per share, boosting the retailer’s share price by approximately 2% on the day.

The profitability increase was linked to improved royalty rates on franchise sales of 0.4%; the increased royalty rates have generally been expected to remain the same over time, with analysts pointing to the fact that improving same-store sales and revenue justify the increase. The increase in royalty rates is also aligned with an increase in professional allowances from generic drug manufacturers and a one-time adjustment from the provincial government relating to prior dispensing revenue, both of which were factors leading to the better-than-expected results this week.

With the Canadian pharmacy business generally outperforming other brick-and-mortar retail operations, such as grocery retail, due to higher margins and sales-per-square foot, long-term investors looking for retail exposure have long considered pharmacies as an excellent growth business.

Jean Coutu remains a unique pharmacy retailer for two main reasons. First, its operations are focused in Quebec, meaning it is uniquely exposed to the political and economic environment of the province. Second, the company is a franchise operation relying on royalty revenue, which is different from other corporate-owned models or hybrid models which are common among other pharmacy chains.

With Jean Coutu’s franchise/royalty model underpinning its growth strategy in eastern Canada, investors must weigh the unique risks associated with investing in a company that is not as geographically diversified as other retailers. That said, should the Quebec economy improve more rapidly than the rest of the country, investors are likely to experience a much larger windfall.

One of the largest tailwinds for Jean Coutu of late has been discussions about how marijuana will be dispensed in Quebec once the drug is legalized. With expectations that pharmacies may be at the front of the line in receiving retail licences for cannabis, investors will be paying close attention to how legalization will roll out and how the licensing program will affect companies like Jean Coutu. Investors bullish on pharmacies’ ability to leverage the “green rush” in Canada have highlighted this possibility as one of the main investment theses to look at Jean Coutu.

In terms of tailwinds, Jean Coutu remains at the wrong end of a pricing dispute between the minister of health of Quebec and the generic drug industry, as generic drug pricing coinciding with a cap on professional allowances (expected to come in at 15%) which is likely to hamper profitability moving forward. While the cap on professional allowances and expected lower drug prices are not expected to take place until the end of next year, investors have begun to price these headwinds in to Jean Coutu’s stock price; with a drop of nearly 13% since the end of April, this pullback may be a great opportunity for investors looking at the pharmacy business to get in.

Stay Foolish, my friends.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any stocks mentioned.

More on Dividend Stocks

Train cars pass over trestle bridge in the mountains
Dividend Stocks

Is CNR Stock a Buy, Sell, or Hold for 2025?

Can CNR stock continue its long-term outperformance into 2025 and beyond? Let's explore whether now is a good time to…

Read more »

coins jump into piggy bank
Dividend Stocks

The Smartest Dividend Stocks to Buy With $500 Right Now

These top dividend stocks both offer attractive yields and trade off their highs, making them two of the best to…

Read more »

Middle aged man drinks coffee
Dividend Stocks

Here’s the Average TFSA Balance at Age 35 in Canada

At age 35, it might not seem like you need to be thinking about your future cash flow. But ideally,…

Read more »

ETF stands for Exchange Traded Fund
Dividend Stocks

How to Invest Your $7,000 TFSA Contribution in 2024

Here's how I would prioritize a $7,000 TFSA contribution for growth and income.

Read more »

a man relaxes with his feet on a pile of books
Dividend Stocks

CPP Pensioners: Watch for These Important Updates

The CPP is an excellent tool for retirees, but be sure to stay on top of important updates like these.

Read more »

Technology
Dividend Stocks

TFSA Investors: 3 Dividend Stocks I’d Buy and Hold Forever

These TSX dividend stocks are likely to help TFSA investors earn steady and growing passive income for decades.

Read more »

four people hold happy emoji masks
Dividend Stocks

Love Dividend Growth? Check Out These 2 Income-Boosting Stocks

National Bank of Canada (TSX:NA) and another Canadian dividend-growth stock are looking like a bargain going into December 2024.

Read more »

An investor uses a tablet
Dividend Stocks

A Dividend Giant I’d Buy Over Enbridge Stock Right Now

Enbridge stock may seem like the best of the best in terms of dividends, but honestly this one is far…

Read more »